Q: Hi 5i, pls provide your opinion on this mornings 1st quarter results release. The numbers and increase in forward guidance look great. Would your estimate for FY24 earnings change from .22? Estimate for FY25? Thx.
You can view 3 more answers this month. Sign up for a free trial for unlimited access.
Investment Q&A
Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.
-
Eli Lilly and Company (LLY $711.68)
-
McKesson Corporation (MCK $689.45)
-
Novo Nordisk A/S (NVO $56.98)
Q: No healthcare exposure other than WELL, could you compare these, or if you have a better idea?
-
Abbott Laboratories (ABT $132.59)
-
Danaher Corporation (DHR $211.80)
-
Eli Lilly and Company (LLY $711.68)
-
Thermo Fisher Scientific Inc (TMO $499.99)
-
Novo Nordisk A/S (NVO $56.98)
-
iShares Global Healthcare ETF (IXJ $88.31)
-
Health Care Select Sector SPDR (XLV $138.17)
-
WELL Health Technologies Corp. (WELL $4.92)
-
iShares U.S. Healthcare ETF (IYH $58.23)
Q: Can you account for the recent drop in TMO and possibly also for its quick recovery.
Portfolio analytics call for more in my healthcare sector. Do you prefer ETFs or individual companies here?
Please recommend a few of your favourite quality long-term holds for both (more American than Canadian, but both if possible).
Thanks as always.
Portfolio analytics call for more in my healthcare sector. Do you prefer ETFs or individual companies here?
Please recommend a few of your favourite quality long-term holds for both (more American than Canadian, but both if possible).
Thanks as always.
Q: Hi Peter, Ryan, and Team,
We hold IHI in our non-registered investment account, and I recently looked at US News (https://money.usnews.com/investing/articles/best-health-care-etfs-to-buy-now) which stated:
“The main issue holding weight-loss drugs back is their exorbitant price tag, with Ozempic clocking in at $980 per month and Wegovy at up to $1,300 per month. If weight-loss prices fall or if insurers and employers start covering their costs for consumers, that could negatively impact medical device-oriented funds like IHI.”
Do you concur with this view? I note that XLV has surpassed IHI in four out of seven periods from one month to ten years. Alternatively, since Portfolio Analytics indicates that we need to increase Healthcare exposure, would starting a new position in XLV at this time be prudent?
Thanks in advance for your advice.
We hold IHI in our non-registered investment account, and I recently looked at US News (https://money.usnews.com/investing/articles/best-health-care-etfs-to-buy-now) which stated:
“The main issue holding weight-loss drugs back is their exorbitant price tag, with Ozempic clocking in at $980 per month and Wegovy at up to $1,300 per month. If weight-loss prices fall or if insurers and employers start covering their costs for consumers, that could negatively impact medical device-oriented funds like IHI.”
Do you concur with this view? I note that XLV has surpassed IHI in four out of seven periods from one month to ten years. Alternatively, since Portfolio Analytics indicates that we need to increase Healthcare exposure, would starting a new position in XLV at this time be prudent?
Thanks in advance for your advice.
Q: What does the market expect this week?
Thx
Thx
-
Amgen Inc. (AMGN $293.72)
-
Intuitive Surgical Inc. (ISRG $476.16)
-
Eli Lilly and Company (LLY $711.68)
-
WELL Health Technologies Corp. (WELL $4.92)
Q: WELL was $3.50 in August 2020 and its $3.55 today.
Reminds me a lot of GUD. IMHO 5i tends to be overly patient on some failed investments whereby selling them and moving on could make for a much better return.
So I have been as patient as I want to be with WELL. When I sell my shares of WELL, which I intend to do, what would be a good replacement that is well managed and has good potential growth in its future outlook?
And of course, has a proven management team.
Thanks
Sheldon
Reminds me a lot of GUD. IMHO 5i tends to be overly patient on some failed investments whereby selling them and moving on could make for a much better return.
So I have been as patient as I want to be with WELL. When I sell my shares of WELL, which I intend to do, what would be a good replacement that is well managed and has good potential growth in its future outlook?
And of course, has a proven management team.
Thanks
Sheldon
Q: Hi what key points do you identify form the earnings? Does LNTH have serious growth (with profit)? Management had turned me off from investing... your take on management?
Q: Could you please comment on their results and outlook?
Thanks,
Milan
Thanks,
Milan
Q: Your thoughts on Lantheus last quarter report. Do you see this as a good investment for the next 3-5 years, and if so why?
Q: Hi Peter, I'm looking at the WELL.TO chart and see that three times over the past half year there has been a dramatic spike in share price followed by an immediate and equally dramatic sell-off taking the stock lower than the pre-spike level. I know you don't have a crystal ball but you do have a lot of experience with Canadian small/micro caps and was wondering how you interpret this price action. Is it people who lost on the stock and are waiting to recoup some of there losses?
Do you still consider this a undervalued small cap stock? Technically, it is a basket case.
David
Do you still consider this a undervalued small cap stock? Technically, it is a basket case.
David
Q: I have been holding Well for a while now and while dissapointed in the share price I am not dissapointed with the financial results. Allways they could be better but I felt the company is moving in the right direction. I'm struggling with "market sentiment" and how to include this in my investment decisions.
It feels like if I could get a handle on this I could get in front of a stocks ups and downs and adjust my position accordingly.
I'm not expecting a definitive answere but just some advice how to value and navigate "market sentiment." Thanks John
It feels like if I could get a handle on this I could get in front of a stocks ups and downs and adjust my position accordingly.
I'm not expecting a definitive answere but just some advice how to value and navigate "market sentiment." Thanks John
Q: good day to you
what is your opinion about this company and would you add after todays surge ?
thanks for your super service
Georges
what is your opinion about this company and would you add after todays surge ?
thanks for your super service
Georges
Q: Well used the word "partnership" with Microsoft in the release, although it sounds like they are simply using Microsoft products?
Q: Would you add to a small position in a dividend portfolio with this drop?
Q: Why it keeps falling?
Would you buy it?
Thanks,
Milan
Would you buy it?
Thanks,
Milan
Q: Hi,
Long time share holder of Zoetis with a current portfolio weight of 2%. With this pull back is it a good opportunity to add? Or do you feel it is still expensive with the risks of medication side effects affecting business?
Thanks,
Kerri
Long time share holder of Zoetis with a current portfolio weight of 2%. With this pull back is it a good opportunity to add? Or do you feel it is still expensive with the risks of medication side effects affecting business?
Thanks,
Kerri
Q: May I have your comments on Gilead's 1st. Quarter Results and view on this continuing as a Hold. Thanks Gerry.
Q: What is the expressions for Ilmn? And if they match expressions would it be a ok time to dip a toe in for a half position?
Q: Your comments on SVA. Is it a Hold or a Sell? Thanks
Q: Your updated thoughts on IGX. Would you consider it a Buy, Sell, or Hold? Thanks